A group that monitors the U.S. electricity system warns that grid reliability is “worsening” and blackout risks are rising ...

One way leads to a future in which AI-driven breakthroughs remain the exclusive domain of pharmaceutical giants with billion-dollar budgets. The other, to a landscape where breakthroughs regularly ...

It began, like so many memorable music stories do, with a British icon and the younger upstart who loved his style. The icon ...

Ricursive Intelligence, founded by two former Google researchers and valued at $4 billion, is among several efforts to ...

Tommy Oliver is one of the most important Power Rangers and takes on several forms throughout his time on the show.

It's the backbone of any successful home lab ...

Anthropic released Cowork on Monday, a new AI agent capability that extends the power of its wildly successful Claude Code tool to non-technical users — and according to company insiders, the team ...

Google parent Alphabet has agreed to buy Intersect Power, a data center and clean energy developer, for $4.75 billion in cash, plus the assumption of the company’s debt. The acquisition, which was ...

The outcome of what was, until recently, an obscure US power market auction will be the subject of intense interest this week for electric generators, regulators and consumers alike. The results due ...

Before market open, Recursion divulged that its REC-4881 demonstrated notable efficacy in a phase 1b/2 trial. The drug, which treats a disorder called familial adenomatous polyposis (FAP) in which ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

'Mad Money' host Jim Cramer weighs in on stocks including: Recursion Pharmaceuticals and NuScale Power. Got a confidential news tip? We want to hear from you. Sign up for free newsletters and get more ...